Opana-news From Endo Nov 2012
Updated
Endo Health Solutions' CEO Discusses Q3 2012 Results - Earnings Call Transcript
November 5, 2012 | about: ENDP
Looking ahead, new products, devices and services will be one key to our future success. Today our R&D pipeline is poised to deliver important new products beginning in 2013, including select launches of high-value generics during the next two years. We’re investing in new medical devices and practice management services both on our own and in collaboration with other companies. You should begin to see the fruits of those labors starting in 2013 and 2014.
We have multiple opportunities for significant organic growth within our diversified businesses. And as I stated at last month’s analyst meeting, we expect to enhance our growth by continuing to invest in our current commercial portfolio, delivering an expanded value proposition with new products and services through our pipeline and through business development.
We expect Qualitest to deliver year-over-year double-digit sales growth through 2013. This will be supported by increasing our production capacity by 15% annually over the next year, three years to support its growth. We expect to see a return to double-digit prescription growth in products like Voltaren Gel and the reformulated OPANA ER which will drive growth in our branded pharmaceutical businesses.
We also expect that our penetration into the urology market with AMS and HealthTronics which both really touched greater than 80% of the U.S. urologists in the U.S. will support accelerating mid to high single digit growth in these segments.
In summary, I believe our diversification during the past four years has made Endo a much stronger company today and put it on the right strategic path to meet the needs of tomorrow's healthcare system. Our R&D organization is productive. Our sales organization is more efficient and we have demonstrated our ability to develop new healthcare solutions through EMR, practice management and practice analytics. These are all promising platforms to build on for future revenue and earnings growth.
Across all of our businesses we are focused on delivering a strong finish to 2012 and positioning Endo to succeed in 2013. In branded pharmaceuticals, changing momentum, reformulated OPANA ER and returning it to prescription growth is a top priority. We’re collecting an increasing body of data to support our position that higher hurdles should have to be met before generic versions of OPANA ER are permitted to enter the market. We believe it’s important for clear regulatory and market boundaries to be drawn between the current abuse deterrent formulations of products such as OPANA ER and oxycodone and the generic versions of their discontinued formulations that do not meet the abuse deterrent formulations.
Other priorities include with Qualitest we’re focused on improving operating efficiencies and capitalizing on more of our volume opportunities. Our AMS and HealthTronics business are engaging with physicians and patients to raise the awareness of our products and services in both domestic and international markets. And throughout the organization, we are sizing our infrastructure and prioritizing our investments now in order to deliver the expectations we’ve set.
I would now like to turn the call over to Julie McHugh to review our operations during the quarter. Julie?
Julie McHugh
Thank you, Dave. As Dave mentioned returning OPANA ER to a growth trajectory is a top priority from my branded pharmaceuticals, marketing and sales team. We believe that the prospects for returning OPANA ER to growth remains strong.
In the third quarter, we stabilized demand for OPANA ER and marked the transition of this franchise when we announced in September that more than 90% of prescriptions are being filled with OPANA ER that is designed to be crush resistant. Our commitment shared at our analyst day is to return OPANA ER to double digit growth by the end of 2013. With the supply chain stabilized we believe we are poised to return this product to growth. We believe we can create that growth through application of our successful commercial model that is focused on establishing access and then applying targeted effective demand creation in key physician and patient audiences. I will be happy to discuss the details of our efforts further during Q&A.
Single page view
« Previous |
page 2 / 5
| Next »
This transcript was sent to 272 people who get email alerts on ENDP.
Get email alerts on ENDP
More Discussions:
Here is a piece about a group trying to stop pain medicines from being made generic unless its the way they want it made...
3 REPLIESI just saw this. FDA rejects Endo's deadline. Generic Opana will be produced but could change again in May 2013 The ...
7 REPLIESI have been prescribed Opana ER 40 mg three times a day, since 2003. In the last two months it has become unavailable fr...
3 REPLIESSo I heard on the news yesterday that the FDA WANTS to stop production of Endo's Opana. Now my question is are they ...
33 REPLIESI have tried Subutex for 4 month, it does not help my stomach pain and getting worse. I can't enjoy life or my new d...
2 REPLIESI don't like the morphine. My opana worked wonderfully but of course now I can't take it because of those who ar...
1 REPLYHello, I am currently dependent on Opana and every time I lower it I get very sick. My plan is to decrease daily and I&#...
4 REPLIESMy Dr has given me the option to switch from Opana ER 45mg to msCottin ER! How many MG of MSCottin ER will it take to eq...
5 REPLIESThe FDA is asking Endo to completely discontinue making Opana ER. I just wanted to give anyone who is on this medication...
14 REPLIESI have been taking ms contin 15 mg twice a day for a few months and raking it about 4 or 5 times a day the last 4 days s...
6 REPLIES